References: |
Product Reference:
?Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone: J. Sakamoto, et al.; BBRC 278, 704 (2000)
?The PPARs: from orphan receptors to drug discovery: T.M. Willson, et al.; J. Med. Chem. 43, 527 (2000)
?The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones: T.M. Willson, et al.; J. Med. Chem. 39, 665 (1996)
?An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
?benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
?Pioglitazone: beyond glucose control: P. de Pablos-Velasco; Expert Rev. Cardiovasc. Ther. 8, 1057 (2010) Review
?Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase: D. Seto-Young, et al.; Horm. Metab. Res. Epub ahead of print, (2011)
?Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB: C. Ao, et al.; Cell Biol. Int. 34, 723 (2010)
?Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway: H.L. Zhang, et al.; Neuroscience 176, 381 (2011)
? |